Flare Therapeutics: Funding, Investors & Team (Sep 2026)
Flare Therapeutics is a biotech firm that is venturing into a new therapeutic domain by taking a unique approach to decode the biology of transcription factors, in order to develop remedies in the form of small molecule medications. The team at Flare has discovered certain areas known as 'switch sites', which can be targeted for governing transcription factors and correcting mutation-induced ailments. Through its drug discovery program, which primarily centers around precision oncology, Flare has made significant progress in developing a drug pipeline aimed at tackling well-established transcription factors, and is looking to expand into fields such as neurology, immunology and inflammation, as well as rare genetic disorders.
Flare Therapeutics has raised $208M across 2 funding rounds on record, the most recent a Series C of $85.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Flare Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Flare Therapeutics Funding Rounds
Flare Therapeutics raised $123M in a Series B announced in Mar 2023.
3.3 years later, a Series C of $85.0M was announced in Jun 2026.
Flare Therapeutics Founders and Leadership Team
Contact details for the Flare Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Flare Therapeutics Funding Compared to Other Biotechnology Startups
Flare Therapeutics' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Flare Therapeutics in Biotechnology and Cambridge
Companies Similar to Flare Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Flare Therapeutics Funding FAQs
What does Flare Therapeutics do?
Flare Therapeutics is a biotech firm that is venturing into a new therapeutic domain by taking a unique approach to decode the biology of transcription factors, in order to develop remedies in the form of small molecule medications. The team at Flare has discovered certain areas known as 'switch sites', which can be targeted for governing transcription factors and correcting mutation-induced ailments. Through its drug discovery program, which primarily centers around precision oncology, Flare has made significant progress in developing a drug pipeline aimed at tackling well-established transcription factors, and is looking to expand into fields such as neurology, immunology and inflammation, as well as rare genetic disorders.
How much funding has Flare Therapeutics raised?
Flare Therapeutics has raised $208M across 2 rounds on record. The most recent is a Series C of $85.0M announced in Jun 2026.
When did Flare Therapeutics last raise funding?
Flare Therapeutics' most recent funding round on record is a Series C of $85.0M, announced in Jun 2026.
Who founded Flare Therapeutics?
FundedIQ lists Doug Manion (Founder) at Flare Therapeutics.
Who is the CEO of Flare Therapeutics?
Amit Rakhit is listed as CEO at Flare Therapeutics.
Where is Flare Therapeutics headquartered?
Flare Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Flare Therapeutics have?
Flare Therapeutics is in the 11-50 employee band.
How does Flare Therapeutics' funding compare to other Biotechnology startups?
Flare Therapeutics' latest round of $85.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Flare Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Flare Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.